Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Episode 7: Does physician gender matter? Impact on surgical outcomes, patient care and more

    Episode 7: Does physician gender matter? Impact on surgical outcomes, patient care and more

    FromThe View on GU | with Lalani and Wallis

    Start listeningView podcast show

    Episode 7: Does physician gender matter? Impact on surgical outcomes, patient care and more

    FromThe View on GU | with Lalani and Wallis

    ratings:
    Length:
    21 minutes
    Released:
    May 8, 2024
    Format:
    Podcast episode

    Description

    Episode 7 was filmed live in Niagara, Ontario at the 13th Annual Juravinski Cancer Centre and Walker Cancer Centre Uro-oncology Forum! Our hosts discuss Dr. Christopher Wallis’ presentation about physician and surgeon gender and how it impacts patient care, surgical outcomes, mortality and more - especially in the field of genitourinary cancers. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com
    This podcast has been made possible through financial support by AstraZeneca, Bristol Myers Squibb, Merck, and TerSera.
    Released:
    May 8, 2024
    Format:
    Podcast episode

    Titles in the series (11)

    There is currently a lack of organic multi-disciplinary discussion on what is truly impactful to the field of genitourinary (GU) cancers. The View on GU with Lalani and Wallis is a podcast that will integrate key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians. Importantly, Lalani and Wallis will also discuss the impact of governmental approvals and funding considerations on the GU oncology treatment landscape and provide practical considerations on the management of patients on new-to-market therapies.